Bicara Therapeutics Inc. Common Stock (BCAX) NASDAQ

20.00

+0.36(+1.83%)

Updated at June 03 04:00PM

Currency In USD

Bicara Therapeutics Inc. Common Stock

Address

116 Huntington Avenue

Boston, MA 02116

United States of America (the)

Phone

617-468-4219

Website

https://www.bicara.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

September 13, 2024

Key Executives

Name	Title	Pay	Year Born
Claire Mazumdar Clemon	Chief Executive Officer & Director	927,688	1990
David Raben	Chief Medical Officer	709,164	1964
Ryan Cohlhepp	President, Chief Operating Officer & Director	858,400	1977
Ivan Hyep	CFO & Treasurer	915,375	1985
Lara S. Meisner	Chief Legal Officer, Compliance Officer & Corporate Secretary	0	1972
Pauline Dufresne	Chief People Officer	0	N/A
Rachel Frank	Vice President of Investor Relations and Corporate Communications	0	N/A
Angela Windt	Vice President & Head of Regulatory Affairs	0	N/A
Sathish Hasige	Senior Vice President and Head of Technical Operations & Supply Chain	0	N/A
Gary Bostanxhi	Vice President of Finance & Controller	0	N/A
Rachel Salazar	SVP of R&D Strategy and Operations	0	N/A
Jeltje Schulten	Senior Vice President of Clinical & Medical Affairs	0	N/A
Jean-Paul Rodrique	Senior Vice President & Global Head of Quality Assurance	0	N/A
Jenna Cohen	Chief Corporate Affairs Officer	0	N/A
Tanya Green	Chief Development Officer	0	N/A

Description

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.